Ali Rezaie1, Sung Chul Park2,3, Walter Morales2, Emily Marsh2, Anthony Lembo4, Jae Hak Kim5, Stacy Weitsman2, Kathleen S Chua2, Gillian M Barlow2, Mark Pimentel2. 1. GI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, 8730 Alden Drive, Thalians Bldg, #E226, Los Angeles, CA, 90048, USA. ali.rezaie@cshs.org. 2. GI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, 8730 Alden Drive, Thalians Bldg, #E226, Los Angeles, CA, 90048, USA. 3. Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea. 4. Beth Israel Deaconess Medical Center, Boston, MA, USA. 5. Department of Internal Medicine, Dongguk University Ilsan Hospital, The Graduate School of Dongguk University, Goyang, South Korea.
Abstract
BACKGROUND: Antibodies to cytolethal distending toxin B (CdtB) and vinculin are novel biomarkers that rule-in and differentiate irritable bowel syndrome with diarrhea (IBS-D) from other causes of diarrhea and healthy controls. AIM: To determine whether these antibodies can also diagnose and differentiate other IBS subtypes. METHODS: Subjects with IBS-D based on Rome III criteria (n = 2375) were recruited from a large-scale multicenter clinical trial (TARGET 3). Healthy subjects without gastrointestinal (GI) diseases or symptoms (n = 43) and subjects with mixed IBS (IBS-M) (n = 25) or IBS with constipation (IBS-C) (n = 30) were recruited from two major medical centers. Plasma levels of anti-CdtB and anti-vinculin antibodies in all subjects were determined by enzyme-linked immunosorbent assay. Optical densities of ≥1.68 and ≥2.80 were considered positive for anti-vinculin and anti-CdtB, respectively. Plasma levels of anti-CdtB and anti-vinculin antibodies were highest in IBS-D and lowest in IBS-C and healthy controls (P < 0.001). Levels in IBS-C subjects were not statistically different from controls (P > 0.1). Positivity for anti-CdtB or anti-vinculin resulted in a statistically significant negative gradient from IBS-D (58.1%) to IBS-M (44.0%), IBS-C (26.7%), and controls (16.3%) (P < 0.001). CONCLUSIONS: Anti-CdtB and anti-vinculin titers and positivity rates differ in IBS subtypes, with higher antibody levels and positivity rates in IBS-D and IBS-M, and lower levels in IBS-C subjects that are similar to those in healthy controls. These antibodies appear useful in the diagnosis of IBS-M and IBS-D, but not IBS-C. Furthermore, these findings suggest that IBS-C is pathophysiologically distinct from subtypes with diarrheal components (i.e., IBS-M and IBS-D).
BACKGROUND: Antibodies to cytolethal distending toxin B (CdtB) and vinculin are novel biomarkers that rule-in and differentiate irritable bowel syndrome with diarrhea (IBS-D) from other causes of diarrhea and healthy controls. AIM: To determine whether these antibodies can also diagnose and differentiate other IBS subtypes. METHODS: Subjects with IBS-D based on Rome III criteria (n = 2375) were recruited from a large-scale multicenter clinical trial (TARGET 3). Healthy subjects without gastrointestinal (GI) diseases or symptoms (n = 43) and subjects with mixed IBS (IBS-M) (n = 25) or IBS with constipation (IBS-C) (n = 30) were recruited from two major medical centers. Plasma levels of anti-CdtB and anti-vinculin antibodies in all subjects were determined by enzyme-linked immunosorbent assay. Optical densities of ≥1.68 and ≥2.80 were considered positive for anti-vinculin and anti-CdtB, respectively. Plasma levels of anti-CdtB and anti-vinculin antibodies were highest in IBS-D and lowest in IBS-C and healthy controls (P < 0.001). Levels in IBS-C subjects were not statistically different from controls (P > 0.1). Positivity for anti-CdtB or anti-vinculin resulted in a statistically significant negative gradient from IBS-D (58.1%) to IBS-M (44.0%), IBS-C (26.7%), and controls (16.3%) (P < 0.001). CONCLUSIONS: Anti-CdtB and anti-vinculin titers and positivity rates differ in IBS subtypes, with higher antibody levels and positivity rates in IBS-D and IBS-M, and lower levels in IBS-C subjects that are similar to those in healthy controls. These antibodies appear useful in the diagnosis of IBS-M and IBS-D, but not IBS-C. Furthermore, these findings suggest that IBS-C is pathophysiologically distinct from subtypes with diarrheal components (i.e., IBS-M and IBS-D).
Authors: Brennan M R Spiegel; Mary Farid; Eric Esrailian; Jennifer Talley; Lin Chang Journal: Am J Gastroenterol Date: 2010-03-02 Impact factor: 10.864
Authors: Sally D Parry; Rosamund Stansfield; Diana Jelley; Wendy Gregory; Elizabeth Phillips; J Roger Barton; Mark R Welfare Journal: Am J Gastroenterol Date: 2003-02 Impact factor: 10.864
Authors: Alice E Zemljic-Harpf; Sornya Ponrartana; Roy T Avalos; Maria C Jordan; Kenneth P Roos; Nancy D Dalton; Vinh Q Phan; Eileen D Adamson; Robert S Ross Journal: Am J Pathol Date: 2004-09 Impact factor: 4.307
Authors: Marta Pozuelo; Suchita Panda; Alba Santiago; Sara Mendez; Anna Accarino; Javier Santos; Francisco Guarner; Fernando Azpiroz; Chaysavanh Manichanh Journal: Sci Rep Date: 2015-08-04 Impact factor: 4.379
Authors: Matthew Silbergleit; Adrian A Vasquez; Carol J Miller; Jun Sun; Ikuko Kato Journal: Prog Mol Biol Transl Sci Date: 2020-04-09 Impact factor: 3.622
Authors: Ramesh P Arasaradnam; Steven Brown; Alastair Forbes; Mark R Fox; Pali Hungin; Lawrence Kelman; Giles Major; Michelle O'Connor; Dave S Sanders; Rakesh Sinha; Stephen Charles Smith; Paul Thomas; Julian R F Walters Journal: Gut Date: 2018-04-13 Impact factor: 23.059
Authors: Sunaina Rengarajan; Kathryn A Knoop; Arvind Rengarajan; Jiani N Chai; Jose G Grajales-Reyes; Vijay K Samineni; Emilie V Russler-Germain; Prabha Ranganathan; Alessio Fasano; Gregory S Sayuk; Robert W Gereau; Andrew L Kau; Dan Knights; Purna C Kashyap; Matthew A Ciorba; Rodney D Newberry; Chyi-Song Hsieh Journal: Cell Rep Med Date: 2020-10-20